EGFR and neoplasm: The re-plasticity of the TME, which is characterized by the infiltration of tumor-associated immune cells and the upregulation of immune checkpoint-related proteins, was also responsible for the resistance to anti-EGFR drugs and treatment failure (Misale et al., 2014; Woolston et al., 2019).